

DAFTAR PUSTAKA

1. Rund D, Rachmilewitz E. Medical progress: β -thalassemia. *N Engl J Med*. 2005;353:1135-46.
2. DeBaun MR, Jones, Melissa JF, Vichinsky EP. Thalassemia syndromes. Dalam: Robert M. Kliegman, penyunting. *Nelson Textbook of Pediatrics*. Edisi ke-20 . Philadelphia: Elsevier; 2016.h.. 2349-52.
3. Wahidiyat PA. Komplikasi pada thalassemia mayor. Dalam: Subanada IB, Kumara Wati KD, Sidiartha IGL, Lingga Utama IMGD, Supartha M, Setyorini A dkk, penyunting. *Pendidikan Kedokteran Berkelanjutan Ilmu Kesehatan Anak X FK UNUD/RSUP Sanglah*. Denpasar: Bagian IKA FK UNUD, 2010.h.119-32.
4. Muncie HL, Campbell JS. Alpha and beta thalassemia. *Am Fam Physician* 2009;80:339-44.
5. Permono B, Ugrasena IDG. Hemoglobin Abnormal. Dalam: 4. Permono B, Sutaryo, Ugrasena, Windiastuti E, Abdulsalam M, penyunting. *Buku Ajar Hematologi Onkologi Anak*. Edisi ke-1. Jakarta: BP IDAI; 2006.h.64- 84.
6. WHO. Sickle-cell disease and other haemoglobin disorders. [serial online] [cited 2017 May 23rd]; 2011. Diakses dari : <http://www.who.int/mediacentre/factsheets/fs308/en/>.
7. Arianie CP, Angka Pembawa Sifat Thalassemia Tergolong Tinggi. Diakses dari: <https://www.kemkes.go.id/article/view/19052100003/angka-pembawa-sifat-thalassemia-tergolong-tinggi.html>
8. Ayudhia S, Rini EA. Gangguan Endokrin pada Pasien Thalassemia β Mayor di RSUP Dr. M. Djamil Padang. *Human Care Journal*. 2020;5:20:554-9
9. Alatzoglou KS, Dattani MT. Acquired disorders of the hypothalamo-pituitary axis. Dalam: Brook C, Clayton P, Brown R, penyunting. *Brook's Clinical Pediatric Endocrinology*. Edisi ke-6. West Sussex UK: WileyBlackwell Publishing; 2009.h.106-23.
10. Low LCK. Growth of children with β -thalassemia major. *Indian Pediatr* 2005;72:159-63.
11. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR dkk. Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. *Eur J Pediatr* 1996;155:368-72.
12. Saxena A. Growth Retardation in thalassemia major patients. *Int J Hum Genet* 2003;3:237-46.
13. Roth C, Pekrun A, Bartz M, Jarry H, Eber S, Lakomek M, dkk. Short stature and failure pubertal development in thalassemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. *Eur J Pediatrics* 1997;156:777-83.
14. Borgna-Pignatti C, De Stefano P, Zonta L, Vullo C, De Sanctis V, Melevendi C. Growth and sexual maturation in thalassemia major. *J Pediatr* 1985;106:150–5.
15. Low LCK, Kwan EYW, Lim YJA, Lee CW, Tam CF, Lam KSL. Growth Hormone treatment of short Chinese children with β -thalassaemia major without GH deficiency. *Clinical Endocrinol* 1995;42:359-63.
16. Kwan EYW, Lee ACW, Li AMC, Tam SCF, Chan CF, Lau YL, Low LCK. A Cross-sectional study of growth, puberty and endocrine function in patients with thalassaemia major in Hongkong. *J Paediatr and Child Health* 1998; 34:47-52.

17. Katzos G, Harsoulis F, Papadopoulou M, Athanasiou M, Sava K. Circadian growth hormone secretion in short multitransfused prepubertal children with thalassaemia major. *Eur J Pediatr* 1995;154:445-9.
18. Saenger P, Schwartz E, MarkensoSaenger P, Schwartz E, Markenson AL, Graziano JH, Levine LS, Lew MI. Depressed serum somatomedin activity in β -Thalassemia. *J Pediatr* 1980;96:214-8.
19. De Virgiliis S, Congia M, Frau F, Argioli F, Diana G, Cucca F, dkk. Deferoxamine-induced growth retardation in patients with thalassemia major. *J Pediatr* 1988;113:661-9.
20. Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, dkk. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. *Eur J Haematol* 2005;74:93-100.
21. Rokom. Thalassemia bukan penyakit menular.. Pusat Komunikasi Publik, Sekretariat Jenderal Kementerian Kesehatan RI; 2012. 4.
22. Primadi O. Skrining penting untuk cegah thalassemia. Biro Komunikasi dan Pelayanan Masyarakat, Kementerian Kesehatan RI; 2017.
23. Wahyuni MS, Ali M, Rosdiana N, Lubis B. Quality of life assessment of children with thalassemia. *Paediatrica Indones* 2011;51:163-9.
24. Permono B, Ugrasena IDG. Hemoglobin abnormal. Dalam: Buku ajar hematologi-onkologi anak. Jakarta: Badan Penerbit IDAI; 2012.h..78-81.
25. Pranajaya R, Nurchairina. Faktor yang berhubungan dengan kualitas hidup anak thalassemia. *Jurnal Keperawatan* 2016 ;12:131-40.
26. Higgs DR, Thein SL, Woods WG. The molecular pathology of the thalassaemias. In: Weatherall DJ, Clegg B, editors. *The thalassaemia syndromes*. 4th ed. England: Blackwell Science; 2001. p. 133-91.
27. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β - thalassemia major in North America. *Blood*. 2004;104:34-9.
28. Kwiatkowski JL. Hemoglobinopathies. In: Lanzkowsky P, Lipton JM, Fish JD, editors. *Lanzkowsky's manual of pediatric hematology and oncology*. 6th ed. USA: Elsevier; 2016. p. 186-93.
29. Vichinsky E, Levine L. Standards of care guidelines for thalassemia. Oakland: Children's hospital and research center; 2012. p. 1-24.
30. Olivieri NF. The β -thalassemia. *N Engl J Med*. 1999;341:99-109.
31. Vichinsky EP. Changing patterns of thalassemia worldwide. *Ann N Y Acad Sci*. 2005;1054:18-24.
32. Mengenal thalassemia [Internet]. Indonesia; 2016 [cited 2018 Jan 03]. Available from: <http://www.idai.or.id/artikel/seputar-kesehatan-anak/mengenal-thalassemia>.
33. Pootrakul P, Sirankapracha P, Hemsorach S, Moungsub W, Kumbunlue R, Piangitjagum A, et al. A correlations of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patient with thalassemia. *Blood*. 2000;96:2606-12.
34. Rachmilewitz EA, Schrier S. The pathophysiology of β -thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. *Disorders of hemoglobin: genetics, pathophysiology, and clinical management*. Cambridge, England: Cambridge University Press; 2001. p. 233-51.
35. Advani R, Sorenson S, Shinar E, Lande W, Rachmilewitz E, Schrier SL. Characterization and comparison of the red blood cell membrane damage in severe human α - and β -thalassemia. *Blood*. 1992;79:1058-63.

36. Higgs DR, Thein SL, Wood WG. The pathophysiology of the thalassemias. In: Weatherall DJ, Clegg B, editors. *The thalassaemia syndromes*. 4th ed. England: Blackwell Science; 2001. p. 192-236.
37. Shinar E, Rachmilewitz EA, Lux SE. Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia. *J Clin Invest*. 1989;83:404-10.
38. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassemia: an abnormal serum iron fraction of potential toxicity. *Cell Mol Biol*. 2004;50:147-58.
39. Kuypers EA, deJong K. The role of phosphatidylserine in recognition and removal of erythrocytes. *Cell Mol Biol*. 2004;50:147-58.
40. Tavazzi D, Duca L, Graziadei D, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of β -thalassemia intermedia erythrocytes. *Br J Haematol*. 2001;112:48-50.
41. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. *Blood*. 2022;99:36-43.
42. Centis F, Tabellini L, Lucarelli G, Buffi O, Tonucci P, Persini B, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patient with β -thalassemia major. *Blood*. 2000;96:3624-9.
43. Mathias LA, Fisher TC, Zeng L, Meiselman HJ, Weinberg KI, Hiti AL, et al. Ineffective erythropoiesis in β -thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. *Exp Haematol*. 2000;28:1343-53.
44. Angelucci E, Bai H, Centis F, Bafti MS, Guido L, Ma L, et al. Enhanced macrophagic attack on β -thalassemia major erythroid precursors. *Haematologica*. 2002;87:578-83.
45. Viprakasit V, Origa R. Genetic basis, pathophysiology and diagnosis. In: Cappellini M, Cohen A, Porter J, Taher A, Viprakasit V, editors. *Guidelines for the management of transfusion dependent thalassaemia (TDT)*. 3rd ed. Nicosia: Thalassaemia International Federation; 2014. p. 14-25.
46. Galanello R, Origa R. Beta-thalassemia. *Orphanet Journal of Rare Disease*. 2010;5:1-15.
47. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. *Blood*. 1997;89:736-61.
48. Tubman VN, Fung EB, Vogiatzi M, Thompson AA, Rogers ZR, Neufeld EJ, et al. Guidelines for the standard monitoring of patients with thalassemia: report of the thalassemia longitudinal cohort. *J Pediatr Hematol Oncol*. 2015;37:162-9.
49. Borgna-Pignatti C, Galanello R. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. *Wintrobe's Clinical Hematology*. 2004;42:1319-65.
50. Weatherall DJ, Clegg JB. The β -thalassaemias. In: Weatherall DJ, Clegg JB, editors. *The thalassaemia syndrome*. 4th Ed. London: Blackwell Science; 2001. p. 287-356.
51. Galanello R, Origa R. Beta-thalassemia. *Orphanet J of Rare Disease*. 2010;5:11-5.
52. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. *Blood J*. 1997;89:739-61.
53. Najafipour F, Aliashgarjadeh A, Niafar M, Mobaseri M, Agamohamadzadeh N, Sorkhabi RS. Evaluation of glucose metabolism, thyroid function, growth and development pattern and calcium status in patients with thalassemia major. *Medwel J*. 2008;3:867-73.

54. Hamidah A, Rahmah R, Azmi T, Aziz J, Jamal R. Short stature and truncal shortening in transfusion dependent thalassemia patients: result from a thalassemia center in Malaysia. *Shouteast Asian J.* 2001;32:625-30.
55. Moayeri H, Oloomi Z. Prevalence of growth and puberty failure with respect to growth hormone and gonadotropin secretion in beta-thalassemia major. *Arc Iranian.* 2006; 9:329-34.
56. Bhala AK, Marwaha RK, Kaur H. Longitudinal growth attainments of transfusion dependent β -thalassemia children. *Mankin quarterly.* 2008;48:484-93.
57. Saxena A. Growth retardation in thalassemia major patients. *Int J Hum Genet.* 2003;4:237-46.
58. Kyriakou A, Skordis N. Thalassemia and aberration of growth and puberty. *Medit J Hemat Infec Dis.* 2009;4:1-8.
59. Grimberg A, Leon DD. Disorders of growth. In: Mosang T, editor. *Pediatric endocrinology.* Philadelphia: Elsevier Mosby; 2005. p. 127-67
60. Batubara J, Susanto R, Cahyono HA. Pertumbuhan dan gangguan pertumbuhan. In: Batubara J, Trijaya B, Pulungan AB, editors. *Buku ajar endokrinologi anak.* Jakarta: Ikatan Dokter Anak Indonesia; 2010. p. 19-41.
61. Patel L, Clayton PE. Normal and disordered growth. In: Brook CGD, Clyton PE, Brown RS, Savage MO, editors. *Clinical pediatric endocrinology.* 5th Ed. Massachusette: Blackwell; 2005. p. 90-111.
62. Dubey AP, Parakh A, Dublish S. Current trends of the management of beta thalassemia. *Ind J Pediatr.* 2008;7:739- 43.
63. Cappellini MD, Congenite CA, Cohlen A, Piga A, Porter J. Guideline for the clinical management of thalassemia. 2nd Ed. Cyprus: Thalassemia International Federation; 2011. p. 64-70.
64. Ibrahim HM, Ayob Y, Mahayiddin AA, Sathar J, Musa Z, Bakri R, et al. Management of transfusion dependent thalassaemia. Malaysia: Ministry of Health Malaysia; 2009. p.1-84.
65. Skordis N. Endocrine investigation and follow up in thalassemia: times for specific guidlines. *Thalassemia reports.* 2011;1:1-16.
66. Sanctis V, Urso, Scialpi, Mangiagli. Endocrine complications in β -thalassemia major. In: Maggio A, Hoffbrand AV, editors. *Clinical aspects and therapy of haemoglobinopathies.* Italy: Proprieta letteraria riservata; 2004. p. 293-310.
67. Faranoush M, Rahiminejad MS, Karamizadeh Z, Ghorbani R, Owji SM. Zinc supplementation effect linear growth in transfusion dependent β thalassemia. *IJBC.* 2008;1:29- 32.
68. Prabhu R, Prabhu V, Prabhu RS. Iron Overload in beta thalassemia –a review. *J Biosci Tech.* 2009;1;20-31.
69. Barton JC, Edwards CQ, Phatak PD, Britton RS, Bacon BR. *Handbook of iron overload.* New York: Cambridge university Press; 2010. p. 233-41.
70. Mehvar A, Azarkeivan A, Faranoush M, Mehvar N, Saberinedjhad J, Ghorbani R. Endocrinopathies with transfusion dependent betha thalassemia. *Pediatr Hem Onk.* 2008;25:187-94.
71. Shamshirzas AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, et al. Metabolic and endocrinologic complications in beta- thalassemia major: a multicenter study in Taheran. *BMC Endocrine Disorders.* 2003;3:1-6.

72. Khan FUR, Khan MH, Ayub T, Shah SH. Frekuensi of complications in beta thalassemia major in D.I. Khan. *Biomedica*. 2007;23:31-3.
73. Soliman AT, Khalafallah H, Ashour R. Growth and factors affecting it in thalassemia major. *Hemoglobin*. 2009;33:116- 26.
74. Low LCK. Growth of children with β -thalassemia major. *Indian J Ped*. 2005;72:159-63.
75. Paulev PE, Calleja GZ. Other hormones and disorders. In: Paulev PE, Calleja GZ, editors. *New human fisiology*. 2nd Ed. Copenhagen: Elsevier; 2010. p. 251-3.
76. Karamifar H, Amirhakimi GH. Linear growth deficiency in β -thalassemia patients: is it growth hormone dependent? *IJMS*. 2002;27:47-50.
77. Fica S, Albu A, Vladareanu F, Barbu C, Bunghez R, Nitu L, et al. Endocrine disorders in β - thalassemia major: cross sectional data. *Act Endocr*. 2005;1:201-12.
78. Roth C, Perkum A, Bartz M, Jarry H, Eber S, Lakomek M. Short stature and failure of pubertal development in thalassemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. *Eur J pediatr*. 1997;156:777-83.
79. Vogiatzi MA, Macklin EA, Tractenberg FL, Fung EB, Cheung AM, Vichinsky E. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassemia syndromes in North America. *British J of haematology*. 2009;146:546-56.
80. Reiter EO, D'Ercole AJ. Disorders of anterior pituitary gland, hypothalamus and growth. In: Rudolf AM, Hotcler MK, Lister G, Siegel NJ, editors. *Rudolf's pediatric*. 23rd Ed. California: McGraw-Hill; 2003. p. 2002.
81. Rindang C, Batubara JL, Amalia P, Satari H. Some aspects of thyroid dysfunction in thalassemia major patients with severe iron overload. *Paediatr indones*. 2011;51:67-72.
82. Eshragi P, Tamaddoni A, Zarifi K, Mohammadhasani A, Aminzadeh M. Thyroid function in major thalassemia patients: is it related to height and chelation therapy? *Casp J Intern Med*. 2011;2:189-93.
83. Angelucci E, Barosi G, Camaschella C, Cappellini DM, Cazzola, Galanello R. Italian society of hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. *Haematologica*. 2008; 93:741-52.
84. Sayani F, Warner M, Wu J, Rieger DW, Humphreys K, Odame I. Guidelines for the clinical care of patient with thalassemia in Canada. Toronto: Thalassemia foundation of Canada; 2009. p. 15-38.
85. Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in β thalassemia major patients. *Hemoglobin*. 2006;2:257-62.
86. Elghany WA. Guidelines for monitoring and management of endocrine function in children and adolescents with β thalassemia major. University Hospital of Leicester. 2010;1-4.
87. Hindmarsh PC, Swift PGF. An assessment of growth hormone provocation tests. *Arch dis*. 1995;72:362-68.
88. Lee PA, Germak J, Gut R, Khutoryansky N, Ross J. Identification of factors associated with good response to growth hormone therapy in children with short stature: result from the ANSWER program. *Int J pediatric endocrinol*. 2011;6:1-7.
89. Darendaliler F. Safety of growth hormone treatment. *J Clin Res Ped endo*. 2009;1:36-43.

90. Kirk J, Butler G. Treatment of children with recombinant human growth hormone (r-hGH) shared care guidelines. London: British society for paediatric endocrinology and diabetes (BSPED); 2006. p. 1-6.**
91. Permono B, Ugrasena IDG. Hemoglobin abnormal. Dalam: Permono HB, Sutaryo, Ugrasena IDG, Windiastuti E, Abdulsalam M. Buku ajar hematologi-onkologi anak. Jakarta: Ikatan Dokter Anak Indonesia; 2006. h.64-84
92. Ismail A, Campbell MJ, Ibrahim HM, Jones GL. Health related quality of life in Malaysian children with thalassaemia. *Biomed*. 2006; 4:1-8
93. Ermaya YS, Hilmanto D, Reniarti L. Hubungan kadar hemoglobin sebelum transfusi dan zat pengikat besi dengan kecepatan pertumbuhan penderita thalassemia mayor. *Majalah Kedokteran Indonesia*. 2007; 57:380-4
94. Ganie RA. Thalassemia: permasalahan dan penanganannya. Disampaikan pada Pidato Pengukuhan Jabatan Guru Besar Tetap Universitas Sumatera Utara, Medan, 16 November 2005
95. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders : an increasing global health problem. *Bull WHO*. 2001; 79:704-12
96. Thavorncharoensap M, Torcharus K, Nuchprayoon I, Riewpaiboon A, Indaratna K, Ubol B. Factors affecting health-related quality of life in Thai children with thalassemia. *Biomed*. 2010; 10:1-10.
97. Telfer P, Constantinidou G, Andreou P, Christou S, Modell B, Angastiniotis M. Quality of life in thalassemia. *Ann N Y Acad Sci*. 2005; 1054:273-82.
98. Sharghi A, Karbakhsh M, Nabaei B, Meysamie A, Farrokhi A. Depression in mothers of children with thalassemia or blood malignancies: a study from Iran. *Biomed*. 2006; 2:1-5.
99. Olivieri NF, Weatherall DJ. Thalassemias. In: Arcenci RJ, Hann IM, Smith OP, editors. *Pediatric hematology*. Australia: Blackwell Publishing; 2006. h.281-301.
100. Honig GR. Thalassemia syndromes. Dalam: Behrman RE, Kliegman RM, Arvin AN, penyunting. *Nelson textbook of pediatrics*. Edisi ke 15. Philadelphia: Saunders Elsevier; 1996. h.1401-4.
100. Nienhuis AW, Wolfe L. The thalassemias. In: Nathan DG, Oski FA, editors. *Hematology of infancy and childhood*. Philadelphia: Saunders Company; 1987. h.699-763
101. Marengo-Rowe AJ. The thalassemias and related disorders. *Proc*. 2007; 20:27-31
- 102.103. Rahman MJ, Rahman MH. Prevention & control strategy of thalassemia in Bangladesh. *The Orion Med J*. 2003; 16:121-2
- 103.104. Olivieri NF. The β -thalassemias. *Med Progr*. 1999; 341:99-107
104. Rund D, Rachmilewitz E. β thalassemia. *N Eng J Med*. 2005; 353:1135-46
105. Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life : results from a literature review. *Biomed*. 2006; 4:1-6
106. Ikram N, Hassan K, Younas M, Amanat S. Ferritin levels in patients of beta thalassaemia major. *Intern J of Pathol*. 2004; 2:71-4
107. Ali M, Putra ST, Gatot D, Sastroasmoro S. Left ventricular functions and mass of the adolescents and young adults with thalassemia major: an echocardiography study. *Paediatr Indones*. 2006; 46:1-6
108. Wood JC, Tyszkla MT, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. *Am Soc of Hematol*. 2004; 103:1934-6

- 109.Said M, Sastroasmoro S, Gatot D, Supriyatno B, Ananta Y. Comparison of pulmonary function of thalassemic and of healthy children. *Paediatr Indones*. 2005; 45:1-6
- 110.Bridges KR, Pearson HA. Anemias and other red cell disorders. Edisi pertama. New York: Medical Publishing Division; 2008. h.278-301
- 111.Pignatti CB, Rugolotto S, Stefano P, Zhao H, Cappellini MD,Vecchio GC,dkk. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. *Haematol*. 2004; 89:1187-93
- 112.Fica S, Albu A, Vladareanu F, Barbu C, Bunghez R, Nitu L, dkk. Endocrine disorders in β thalassemia major: cross-sectional data. *Act Endocr*. 2005; 1:201-12
- 113.Mazzone L, Battaglia L, Andreozzi F, Romeo MA, Mazzone D. Emotional impact in β thalassaemia major children following cognitive behavioural family therapy and quality of life of caregiving mothers. *Biomed*. 2009; 5:1-6
- 114.Shaligram D, Girimaji SC, Chatutvedi SK. Psychological problems and Quality of life in children with thalassemia. *Indian J of Ped*. 2007; 74:727-30
- 115.Spieth LE, Harris CV. Assessment of health-related quality of life in children and adolescents: an integrative review. *J of Ped Psych*. 1996; 21:175-93
- 116.Palermo TM, Long AC, Lewandowski AS, Drotar D, Quittner AL, Walker LS. Evidence-based assessment of health-related quality of life and functional impairment in pediatric psychology. *J of Ped Psych*. 2008; 33:983-96
- 117.Gallo AD, Puig RF, Topf RJ. Quality of life from research and clinical perspectives: an example from paediatric psycho-oncology. *Clin Chil Psychol and Psychi*. 2007; 12:599-610
- 118.Testa MA, Simonson DC. Assessment of quality of life outcomes. *NEJM*. 1996; 334:835-40
- 119.Vincent KA, Higginson IJ. Assessing quality of life in children. Dalam: Carr AJ, Higginson IJ, Robinson PG. *BMJ books*. London: British Library Cataloguing; 2003. h.40-50
- 120.Sitairesmi MN. Penilaian kualitas hidup yang berhubungan dengan kesehatan (health related quality of life). Presented at PIT IV IKA , Medan, February 20-22, 2010
- 121.Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQLTM in pediatric cancer reliability and validity of the pediatric quality of life inventoryTM generic core scales, multidimensional fatigue scale, and cancer module. *Am Canc Soc*. 2002;10:2090-105
- 122.Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the pediatric quality of life inventory TM version 4.0 generic core scales in healthy and patient population. *Med Care*. 2000; 39:800-12
- 123.Baars RM, Atherton CI, Koopman HM, Bullinger M, Power M, DISABKIDS group. The european DISABKIDS project: development of seven condition-specific modules to measure health related quality of life in children and adolescents. *Biomed*. 2005; 3:1-9
- 124.Ewing JE, King MT, Smith NF. Validation of modified forms of the PedsQL generic core scales and cancer module scales for adolescents and young adults (AYA) with cancer or a blood disorders. *Qual Life Res*. 2009; 18:231-44
- 125.Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Doxon P. The PedsQLTM family impact module: preliminary reliability and validity. *Biomed*. 2004; 55:1-6
- 126.Upton P, Eiser C, Cheung I, Hutchings HA, Jenney M, Maddocks A, dkk. Measurement properties of the UK-English version of the pediatric quality of life inventory 4.0 (PedsQL) generic core scale. *Biomed*. 2005; 3:1-7

- 127.Varni JW, penyunting. Scaling and scoring of the pediatric quality of life inventory PedsQL. USA: College of Architecture; 2005
- 128.Wahidiyat WI. Genetic problems at present and their challenges in the future: thalassemia as a model. Paediatr Indones. 2006; 46:189-94
- 129.Madiyono B, Moeslichan S, Sastroasmoro S, Budiman I, Purwanto SH. Perkiraan besar sampel. Dalam: Sastroasmoro S, Ismael S, penyunting. Dasar-dasar metodologi penelitian klinis. Edisi 3. Jakarta: 2008.h.302-31
- 130.Tyagi S, Kabra M, Tandon N, Saxena R, Pati H P, Choudhry V P. Clinico-haematological profile of thalassemia intermedia patients. Int J Hum Genet. 2003; 3:251-8
- 131.Kaplan HI, Sadock BJ, Grebb JA. Klasifikasi dalam psikiatri dan skala penilaian psikiatri. Dalam: Kaplan HI, Sadock BJ, Grebb JA. Sinopsis psikiatri. Edisi ke 7. Jakarta: Binarupa Aksara; 1997.h.467-501
- 132.Fung EB, Xu Y, Kwiatkowski JL, Vogiatzi MG, Neufeld E, Olivieri N, dkk. Relationship between chronic transfusion therapy and body composition in subjects with thalassemia. J Pediatr. 2010; 64:1-7
- 133.Fuchs GJ, Tienboon P, Linpisarn S, Nimsakul S, Leelapat P, Tovanabutra S, dkk. Nutritional factors and thalassaemia major. Arch Dis Child. 1996; 74:224-7